These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Clinical Outcome
30 results:

  • 1. Peroxiredoxin-2 represses nras-mutated melanoma cells invasion by modulating EMT markers.
    Noma IHY; Carvalho LADC; Camarena DEM; Silva RO; Moraes Junior MO; de Souza ST; Newton-Bishop J; Nsengimana J; Maria-Engler SS
    Biomed Pharmacother; 2024 Aug; 177():116953. PubMed ID: 38955087
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
    Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
    Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
    Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
    JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Correlation of Baseline tumor Burden with clinical outcome in Melanoma Patients Treated with Ipilimumab.
    Angelova-Toshkina D; Weide B; Tietze LF; Hebst M; Tietze JK
    Oncology; 2024; 102(1):76-84. PubMed ID: 37579734
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognostic biomarkers for survival in mucosal melanoma.
    Thierauf JC; Kaluziak ST; Codd E; Dybel SN; Jobbagy S; Purohit R; Farahani AA; Dedeilia A; Naranbhai V; Hoang MP; Fisch AS; Ritterhouse L; Boland GM; Lennerz JK; Iafrate AJ
    Pigment Cell Melanoma Res; 2023 Sep; 36(5):378-387. PubMed ID: 37390098
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The A to I editing landscape in melanoma and its relation to clinical outcome.
    Amweg A; Tusup M; Cheng P; Picardi E; Dummer R; Levesque MP; French LE; Guenova E; Läuchli S; Kundig T; Mellett M; Pascolo S
    RNA Biol; 2022 Jan; 19(1):996-1006. PubMed ID: 35993275
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with clinical outcome.
    Lassalle S; Nahon-Esteve S; Frouin E; Boulagnon-Rombi C; Josselin N; Cassoux N; Barnhill R; Scheller B; Baillif S; Hofman P
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266349
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
    Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
    Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
    Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
    J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome.
    Kenawy N; Kalirai H; Sacco JJ; Lake SL; Heegaard S; Larsen AC; Finger PT; Milman T; Chin K; Mosci C; Lanza F; Moulin A; Schmitt CA; Caujolle JP; Maschi C; Marinkovic M; Taktak AF; Heimann H; Damato BE; Coupland SE
    Pigment Cell Melanoma Res; 2019 Jul; 32(4):564-575. PubMed ID: 30672666
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Gynecologic melanomas: A clinicopathologic and molecular analysis.
    Udager AM; Frisch NK; Hong LJ; Stasenko M; Johnston CM; Liu JR; Chan MP; Harms PW; Fullen DR; Orsini A; Thomas DG; Lowe L; Patel RM
    Gynecol Oncol; 2017 Nov; 147(2):351-357. PubMed ID: 28844540
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
    Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
    Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Congenital melanocytic nevi: update in genetics and management.
    Price HN
    Curr Opin Pediatr; 2016 Aug; 28(4):476-82. PubMed ID: 27307047
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. MAP kinase pathway gene copy alterations in nras/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Analysis of BRAF and nras Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
    Mangana J; Cheng PF; Schindler K; Weide B; Held U; Frauchiger AL; Romano E; Kähler KC; Rozati S; Rechsteiner M; Moch H; Michielin O; Garbe C; Hauschild A; Hoeller C; Dummer R; Goldinger SM
    PLoS One; 2015; 10(10):e0139438. PubMed ID: 26426340
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
    Vízkeleti L
    Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
    Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
    Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Association between BRAFV600E and nrasQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.
    Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA
    Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
    Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.